Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Johnson and Johnson
AstraZeneca
Medtronic
McKinsey

Last Updated: August 15, 2022

EQUETRO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Equetro, and what generic alternatives are available?

Equetro is a drug marketed by Validus Pharms and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has one patent family member in one country.

The generic ingredient in EQUETRO is carbamazepine. There are twenty-seven drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Equetro

A generic version of EQUETRO was approved as carbamazepine by TARO on October 3rd, 1996.

  Try it Free

Summary for EQUETRO
Drug patent expirations by year for EQUETRO
Drug Prices for EQUETRO

See drug prices for EQUETRO

Recent Clinical Trials for EQUETRO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Validus PharmaceuticalsPhase 4
Creighton UniversityPhase 4
Tuscaloosa Research & Education Advancement CorporationPhase 4

See all EQUETRO clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for EQUETRO
Paragraph IV (Patent) Challenges for EQUETRO
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EQUETRO Extended-release Capsules carbamazepine 100 mg 021710 1 2014-05-23
EQUETRO Extended-release Capsules carbamazepine 200 mg and 300 mg 021710 1 2007-08-21

US Patents and Regulatory Information for EQUETRO

EQUETRO is protected by one US patents.

Patents protecting EQUETRO

Methods for the treatment of bipolar disorder using carbamazepine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-001 Dec 10, 2004 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-002 Dec 10, 2004 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-003 Dec 10, 2004 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EQUETRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-003 Dec 10, 2004 See Plans and Pricing See Plans and Pricing
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-001 Dec 10, 2004 See Plans and Pricing See Plans and Pricing
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-002 Dec 10, 2004 See Plans and Pricing See Plans and Pricing
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-001 Dec 10, 2004 See Plans and Pricing See Plans and Pricing
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-002 Dec 10, 2004 See Plans and Pricing See Plans and Pricing
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-003 Dec 10, 2004 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for EQUETRO

See the table below for patents covering EQUETRO around the world.

Country Patent Number Title Estimated Expiration
Canada 2114014 SYSTEME D'ADMINISTRATION DE MEDICAMENT ET METHODE POUR TRAITER A L'AIDE DE LA CARBAMAZEPINE LES TROUBLES PSYCHIATRIQUES, NEUROLOGIQUES ET AUTRES (ADVANCED DRUG DELIVERY SYSTEM AND METHOD OF TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMAZEPINE) See Plans and Pricing
Spain 2137948 See Plans and Pricing
European Patent Office 0660705 SYSTEME ET METHODE PERFECTIONNES D'ADMINISTRATION DE MEDICAMENTS ET DE TRAITEMENT DES AFFECTIONS PSYCHIATRIQUES, NEUROLOGIQUES ET AUTRES AVEC LA CARBAMAZEPINE (ADVANCED DRUG DELIVERY SYSTEM AND METHOD OF TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMAZEPINE) See Plans and Pricing
Canada 2452588 METHODE DE TRAITEMENT DE TROUBLES AFFECTIFS BIPOLAIRES A L'AIDE DE CARBAMAZEPINE (METHODS FOR THE TREATMENT OF BIPOLAR DISORDER USING CARBAMAZEPINE) See Plans and Pricing
Japan H06511484 See Plans and Pricing
Denmark 0660705 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.